178 related articles for article (PubMed ID: 35386697)
1. Negative Effects of Stromal Neutrophils on T Cells Reduce Survival in Resectable Urothelial Carcinoma of the Bladder.
Yang M; Wang B; Hou W; Yu H; Zhou B; Zhong W; Liu Z; Li J; Zeng H; Liu C; Qin H; Lin T; Huang J
Front Immunol; 2022; 13():827457. PubMed ID: 35386697
[TBL] [Abstract][Full Text] [Related]
2. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
3. PD-1 topographically defines distinct T cell subpopulations in urothelial cell carcinoma of the bladder and predicts patient survival.
Hou W; Xue M; Shi J; Yang M; Zhong W; Fan X; Zeng H; Lai Y; Huang J; Wang B; Lin T
Urol Oncol; 2020 Aug; 38(8):685.e1-685.e10. PubMed ID: 32409198
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target.
Raja D; Singh A; Kurra S; Nayak B; Kaushal S; Sharma A; Singh P
Med Oncol; 2024 Feb; 41(3):74. PubMed ID: 38376603
[TBL] [Abstract][Full Text] [Related]
5. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
[TBL] [Abstract][Full Text] [Related]
6. Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder.
Wang B; Xie S; Bi J; Liu Z; Zeng H; Huang H; Xue M; He Z; Yang M; Yu H; Huang J; Lin T
Histopathology; 2019 Sep; 75(3):354-364. PubMed ID: 30653702
[TBL] [Abstract][Full Text] [Related]
7. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
[TBL] [Abstract][Full Text] [Related]
8. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
[TBL] [Abstract][Full Text] [Related]
9. Single-cell atlases link macrophages and CD8
Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
[No Abstract] [Full Text] [Related]
10. PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway.
Liu JY; Qian D; He LR; Li YH; Liao YJ; Mai SJ; Tian XP; Liu YH; Zhang JX; Kung HF; Zeng YX; Zhou FJ; Xie D
Mol Cancer; 2013 Nov; 12(1):148. PubMed ID: 24268029
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
[TBL] [Abstract][Full Text] [Related]
13. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
14. Urine Lactoferrin as a Potential Biomarker Reflecting the Degree of Malignancy in Urothelial Carcinoma of the Bladder.
Matsumura E; Kosuge N; Nakanishi S; Suda T; Sugawa A; Fujimura T; Miyagi R; Yoshimi N; Saito S
Tohoku J Exp Med; 2020 Nov; 252(3):225-244. PubMed ID: 33162487
[TBL] [Abstract][Full Text] [Related]
15. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
16. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer.
Liu K; Zhao K; Wang L; Sun E
Pathol Res Pract; 2018 Aug; 214(8):1074-1080. PubMed ID: 29803657
[TBL] [Abstract][Full Text] [Related]
17. Single-cell transcriptomic analysis of tumor heterogeneity and intercellular networks in human urothelial carcinoma.
Jin X; Wang Q; Luo F; Pan J; Lu T; Zhao Y; Zhang X; Xiang E; Zhou C; Huang B; Lu G; Chen P; Shao Y
Chin Med J (Engl); 2023 Mar; 136(6):690-706. PubMed ID: 36939254
[TBL] [Abstract][Full Text] [Related]
18. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
[TBL] [Abstract][Full Text] [Related]
19. Microlocalization and clinical significance of stabilin-1
Wang B; Huang H; Yang M; Yang W; Liu Z; Hou W; Zeng H; He Z; Lin T; Huang J
World J Urol; 2020 Mar; 38(3):709-716. PubMed ID: 31302753
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Davick JJ; Frierson HF; Smolkin M; Gru AA
Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
